EVERSANA and Waltz Health have jointly confirmed a merger to form one unified healthcare platform, capable of rewriting the rules around pharmaceutical commercialization and patient access.
According to certain reports, the stated move effectively integrates Waltz Health’s software-powered drug-price marketplaces and direct-to-payer model into EVERSANA’s global commercialization services so to create a next-generation approach for drug access and value in the U.S. healthcare system.
More on the same would reveal how such a merger will prove as especially useful in the context of cutting down on the associated with specialty medications and high-cost drug classes like GLP-1s. For instance, this the newly-formed company will largely achieve on the back of Waltz’s technology platform, including its AI-powered prescription routing and affordability solution which connects patients, health insurers, self-insured employers, governments and pharmacy benefit managers (PBMs).
“This is a pivotal moment for the healthcare industry. By combining EVERSANA’s pharma services with Waltz’s technology-enabled payer solutions, we’re creating a unified platform that connects life sciences innovation directly to the organizations and individuals we’re meant to serve. This model is built to accelerate access, improve outcomes and deliver smarter, more transparent drug commercialization at every step,” said Mark Thierer, Co-founder and CEO of Waltz Health and now Chairman of EVERSANA.
Taking a deeper view of all the benefits this merger could very well deliver, we begin from the pharma commercialization, an area where the combined organization will integrate patient services, field teams, digital marketing, reimbursement support and real-world evidence, all powered by modern software infrastructure.
Next up, we have the prospect of payer connectivity. This translates to how Waltz’s direct-to-payer and direct-to-patient solutions will supercharge the EVERSANA COMPLETE Commercialization™ model, thus giving manufacturers turnkey channels to reach millions of covered lives.
Another detail worth a mention is rooted in the potential for greater drug affordability and adherence. You see, by working together, the two companies can enable net-price models, copay optimization and integrated pharmacy routing, components that will reduce patient abandonment and increase therapeutic persistence.
Rounding up highlights would be the access to specialty pharmacy infrastructure. The new company will essentially leverage Waltz Connect, a technology-powered, end-to-end solution that gives payers flexibility and optimized specialty pharmacy saving, to help achieve a fully integrated, URAC-accredited specialty pharmacy network purpose-built for high-cost therapies and limited distribution drugs.
We referred to how Waltz’s technology would be core to making the given merger a success, but what we haven’t touched upon would be the ways in which EVERSANA’s own statures makes such a development hugely critical.
Founded in 2018, EVERSANA’s rise up the ranks stems from offering integrated solutions spanning all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners, and payers.
The company’s excellence in what it does can also be understood once you consider it serves, at present, more than 650 organizations, including innovative start-ups and established pharmaceutical companies.
“This combination brings together the scale and services of EVERSANA with Waltz Health’s payer-integrated platforms to create a company purpose-built for the future of life sciences,” said Thierer. “Together, we are launching a new-to-the-world model that directly connects manufacturers to patients and payers, delivering significant cost savings and improved patient outcomes to the healthcare system.”
